🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

A Global Challenge

Cases of gonorrhoea are on the rise globally, with estimates suggesting more than 82 million instances annually. Especially elevated rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per data detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which uses two antibiotics. The study enrolled over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Doctors on the front lines have voiced optimism. Access to a easy-to-administer therapy such as this is seen as a "revolutionary step" for public health efforts. This is deemed essential to reduce the burden of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.